title: Determinants of transmitral inflow pattern 10-14 days after acute myocardial infarction.
abstract: OBJECTIVE
  The administration of thrombolytic therapy after an acute myocardial infarction can reduce the size of the infarct and improve left ventricular function. We used pulsed Doppler to assess left ventricular diastolic function after an acute myocardial infarction in patients treated with recombinant tissue plasminogen activator (rTPA).
  
  
  METHODS
  We studied 104 patients after an acute myocardial infarction, 48 treated with a placebo and 56 with rTPA. They were compared with 36 age-matched controls. The Doppler parameters measured included the early peak in diastolic flow velocity, the peak during atrial contraction, the atrial: early ratio, mean deceleration, deceleration time, and half-filling fraction. Doppler parameters for large and small infarct sizes were compared.
  
  
  RESULTS
  The Doppler parameters did not differ between treatment groups. Compared with the normal controls, significant differences were observed in both treatment groups for the early peak (placebo P < 0.05; rTPA P < 0.001), the atrial: early ratio (placebo P < 0.05; rTPA P < 0.01), and the half-filling fraction (P < 0.001 for both). In patients with large infarcts, the atrial peak was depressed (P = 0.008). Multivariate analysis showed that end-diastolic pressure, age, end-systolic volume, and regional wall motion parameters were major predictors of Doppler parameters.
authors.affiliation: University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: A E
authors.initials: AE
authors.lastname: Aubert
authors.forename: I K
authors.initials: IK
authors.lastname: Jang
authors.forename: T
authors.initials: T
authors.lastname: Brzostek
authors.forename: F
authors.initials: F
authors.lastname: Van de Werf
authors.forename: H
authors.initials: H
authors.lastname: De Geest
mesh_terms: D000328:Adult; D018619:Echocardiography, Doppler, Pulsed; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000503:physiopathology*; D009203:Myocardial Infarction / Q000503:physiopathology* / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016277:Ventricular Function, Left
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator